Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897523860> ?p ?o ?g. }
- W2897523860 endingPage "334" @default.
- W2897523860 startingPage "334" @default.
- W2897523860 abstract "<h3>Importance</h3> The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers. To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic chemotherapies known to induce immunogenic tumor cell death. <h3>Objective</h3> To examine the safety, tolerability, and preliminary clinical activity of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancers. <h3>Design, Setting, and Participants</h3> This phase 1b multicohort study enrolled 33 women with stage IV or locally recurrent triple-negative breast cancers and 0 to 2 lines of prior chemotherapy in the metastatic setting from December 8, 2014, to April 30, 2017, at 11 sites in the United States. The median follow-up was 24.4 months (95% CI, 22.1-28.8 months). <h3>Interventions</h3> Patients received concurrent intravenous atezolizumab and intravenous nab-paclitaxel (minimum 4 cycles). <h3>Main Outcomes and Measures</h3> The primary end point was safety and tolerability. Secondary end points included best overall response rate by Response Evaluation Criteria in Solid Tumors, version 1.1; objective response rate; duration of response; disease control rate; progression-free survival; overall survival; and biomarker analyses. <h3>Results</h3> The 33 women had a median age of 55 years (range, 32-84 years) and received 1 or more doses of atezolizumab. All patients (100%) experienced at least 1 treatment-related adverse event, 24 patients (73%) experienced grade 3/4 adverse events, and 7 patients (21%) had grade 3/4 adverse events of special interest. No deaths were related to study treatment. The objective response rate was 39.4% (95% CI, 22.9%-57.9%), and the median duration of response was 9.1 months (95% CI, 2.0-20.9 months). The disease control rate was 51.5% (95% CI, 33.5%-69.2%). Median progression-free survival and overall survival were 5.5 months (95% CI, 5.1-7.7 months) and 14.7 months (95% CI, 10.1-not estimable), respectively. Concurrent nab-paclitaxel neither significantly changed biomarkers of the tumor immune microenvironment (programmed death-ligand 1, tumor-infiltrating lymphocytes, CD8) nor impaired atezolizumab systemic immune activation (expansion of proliferating CD8+ T cells, increase of CXCL10 chemokine). <h3>Conclusions and Relevance</h3> In this phase 1b trial for metastatic triple-negative breast cancers, the combination of atezolizumab plus nab-paclitaxel had a manageable safety profile. Antitumor responses were observed, including in patients previously treated with a taxane. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT01633970" @default.
- W2897523860 created "2018-10-26" @default.
- W2897523860 creator A5003060935 @default.
- W2897523860 creator A5003433691 @default.
- W2897523860 creator A5009767169 @default.
- W2897523860 creator A5022876688 @default.
- W2897523860 creator A5033313503 @default.
- W2897523860 creator A5035762260 @default.
- W2897523860 creator A5056037326 @default.
- W2897523860 creator A5066879227 @default.
- W2897523860 creator A5069056507 @default.
- W2897523860 creator A5071439910 @default.
- W2897523860 creator A5076699095 @default.
- W2897523860 creator A5090977453 @default.
- W2897523860 date "2019-03-01" @default.
- W2897523860 modified "2023-10-16" @default.
- W2897523860 title "Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up" @default.
- W2897523860 cites W1546771547 @default.
- W2897523860 cites W1994993231 @default.
- W2897523860 cites W2019607817 @default.
- W2897523860 cites W2047902191 @default.
- W2897523860 cites W2057186227 @default.
- W2897523860 cites W2079068389 @default.
- W2897523860 cites W2098683355 @default.
- W2897523860 cites W2099824657 @default.
- W2897523860 cites W2100413206 @default.
- W2897523860 cites W2111786429 @default.
- W2897523860 cites W2112434826 @default.
- W2897523860 cites W2113479349 @default.
- W2897523860 cites W2117972559 @default.
- W2897523860 cites W2120431466 @default.
- W2897523860 cites W2122495232 @default.
- W2897523860 cites W2124427232 @default.
- W2897523860 cites W2125094267 @default.
- W2897523860 cites W2125885282 @default.
- W2897523860 cites W2129288227 @default.
- W2897523860 cites W2134878729 @default.
- W2897523860 cites W2136451551 @default.
- W2897523860 cites W2252550602 @default.
- W2897523860 cites W2293531514 @default.
- W2897523860 cites W2345415641 @default.
- W2897523860 cites W2499376400 @default.
- W2897523860 cites W2511951051 @default.
- W2897523860 cites W2554176272 @default.
- W2897523860 cites W2559804019 @default.
- W2897523860 cites W2560367415 @default.
- W2897523860 cites W2622613223 @default.
- W2897523860 cites W2624483458 @default.
- W2897523860 cites W2646030831 @default.
- W2897523860 cites W2761452338 @default.
- W2897523860 cites W2801270371 @default.
- W2897523860 cites W2801956643 @default.
- W2897523860 cites W2805354595 @default.
- W2897523860 cites W2883774000 @default.
- W2897523860 cites W2889746019 @default.
- W2897523860 cites W2902530914 @default.
- W2897523860 doi "https://doi.org/10.1001/jamaoncol.2018.5152" @default.
- W2897523860 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6439843" @default.
- W2897523860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30347025" @default.
- W2897523860 hasPublicationYear "2019" @default.
- W2897523860 type Work @default.
- W2897523860 sameAs 2897523860 @default.
- W2897523860 citedByCount "190" @default.
- W2897523860 countsByYear W28975238602018 @default.
- W2897523860 countsByYear W28975238602019 @default.
- W2897523860 countsByYear W28975238602020 @default.
- W2897523860 countsByYear W28975238602021 @default.
- W2897523860 countsByYear W28975238602022 @default.
- W2897523860 countsByYear W28975238602023 @default.
- W2897523860 crossrefType "journal-article" @default.
- W2897523860 hasAuthorship W2897523860A5003060935 @default.
- W2897523860 hasAuthorship W2897523860A5003433691 @default.
- W2897523860 hasAuthorship W2897523860A5009767169 @default.
- W2897523860 hasAuthorship W2897523860A5022876688 @default.
- W2897523860 hasAuthorship W2897523860A5033313503 @default.
- W2897523860 hasAuthorship W2897523860A5035762260 @default.
- W2897523860 hasAuthorship W2897523860A5056037326 @default.
- W2897523860 hasAuthorship W2897523860A5066879227 @default.
- W2897523860 hasAuthorship W2897523860A5069056507 @default.
- W2897523860 hasAuthorship W2897523860A5071439910 @default.
- W2897523860 hasAuthorship W2897523860A5076699095 @default.
- W2897523860 hasAuthorship W2897523860A5090977453 @default.
- W2897523860 hasBestOaLocation W28975238601 @default.
- W2897523860 hasConcept C121608353 @default.
- W2897523860 hasConcept C126322002 @default.
- W2897523860 hasConcept C143998085 @default.
- W2897523860 hasConcept C197934379 @default.
- W2897523860 hasConcept C203092338 @default.
- W2897523860 hasConcept C2775930923 @default.
- W2897523860 hasConcept C2775949291 @default.
- W2897523860 hasConcept C2776694085 @default.
- W2897523860 hasConcept C2777701055 @default.
- W2897523860 hasConcept C2778375690 @default.
- W2897523860 hasConcept C2779984678 @default.
- W2897523860 hasConcept C2780030458 @default.
- W2897523860 hasConcept C2780110267 @default.
- W2897523860 hasConcept C31760486 @default.
- W2897523860 hasConcept C530470458 @default.